ProKidney

PROK · Nasdaq · United States

Share price · PROK

$1.04-0.34 (-24.64%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.8M (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PROK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Nov 2026-13.5%

    Nothing announced by PROK that day or the session before.

  2. 30 Oct 2026-11.9%
  3. 27 Oct 2026+11.4%
  4. 5 Oct 2026-8.1%
  5. 21 Sep 2026-7.1%

    Nothing announced by PROK that day or the session before.

  6. 21 Aug 2026+13.4%

    Nothing announced by PROK that day or the session before.

  7. 12 Aug 2026-8.1%
  8. 30 Jun 2026+7.9%
  9. 3 Jun 2026-8.9%
  10. 17 Apr 2026+11.8%

Share of unusual movement by asset

For each asset, the share of PROK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Rilparencel(Neo-Kidney Augment / REACT)
Phase 3
Selected renal cells (autologous, paracrine)Cell therapy
Chronic Kidney Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
December 2029 (1)
Rilparencel · Neo-Kidney Augment / REACTPhase 3Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Est. primary completion 2029-12 · NCT05099770 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 November 2025Topline resultRilparencelREGEN-007 Phase 2 results were mixed
8 July 2025Topline resultRilparencelPhase 2 REGEN-007 of rilparencel: statistically significant topline results
ProKidney · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.2M$41M$81M$36M-$39M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.1M$36M$75M$28M-$40M operating cash flowreport ↗
2026-Q1$0.2M$34M$102M$20M-$42M operating cash flowreport ↗
2025-Q3$0.2M$27M$95M$16M-$27M operating cash flowreport ↗
2025-Q2$0.2M$26M$85M$17M-$31M operating cash flowreport ↗
2025-Q1$0.2M$27M$98M$17M-$30M operating cash flowreport ↗
2024-Q3$0$31M$108M$18M-$29M operating cash flowreport ↗
2024-Q2$0$29M$215M$13M-$38M operating cash flowreport ↗
2024-Q1$0$27M$84M$9.5M-$35M operating cash flowreport ↗
2023-Q3—$32M$191M$11M-$24M operating cash flowreport ↗
2023-Q2—$26M$244M$9.1M-$15M operating cash flowreport ↗
2023-Q1—$26M$272M$9.7M-$26M operating cash flowreport ↗
2022-Q3—$21M$506M$30M-$61M operating cash flowreport ↗
2022-Q2—$12M$0.1M$2.3M-$0.2M operating cash flowreport ↗
2022-Q1—$28M$0.1M$4.0M-$0.4M operating cash flowreport ↗
2021-Q3—$15M$4.1M$0.3M-$1.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.9M$114M$109M$17M-$120M operating cash flowreport ↗

For full year 2025, ProKidney reported revenue of $0.89M, up 1012.5% YoY, with R&D spend of $114.12M, down 10.6% YoY. Cash and equivalents were $108.54M, while total cash, cash equivalents and marketable securities were $270.0M. Net loss available to Class A common stockholders was $68.99M, reflecting a quarterly net burn of $68.99M.

The company expects existing cash to fund operations into mid-2027. It remains on track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026, with pivotal topline results expected in Q2 2027, and aligned with the FDA in July 2025 on the accelerated approval pathway using eGFR slope. Positive Phase 2 REGEN-007 results were presented at ASN Kidney Week 2025 and published in CJASN, and expansion of the in-house manufacturing footprint was initiated in Winston-Salem.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.1M$128M$99M$15M-$126M operating cash flowreport ↗
2023-FY$0$107M$61M$8.9M-$90M operating cash flowreport ↗
2022-FY$0$82M$490M—-$77M operating cash flowreport ↗
2021-FY—$46M$0.4M$14M-$50M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 6 sales ($1.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-02Culleton Bruce · director, Chief Executive OfficerAward / grant (derivative)500,000——Form 4
2026-10-28Weber Darin J. · Chief Regulatory OfficerConversion200,000——Form 4
2026-10-28Weber Darin J. · Chief Regulatory OfficerConversion (derivative)200,000——Form 4
2026-10-28Weber Darin J. · Chief Regulatory OfficerConversion (derivative)200,000——Form 4
2026-08-20Pereira Brian JG · directorOpen-market sale222,948$1.42$317KForm 4
2026-08-20Pereira Brian JG · directorOpen-market sale27,052$1.42$38KForm 4
2026-08-19Pereira Brian JG · directorOpen-market sale222,949$1.44$321KForm 4
2026-08-19Pereira Brian JG · directorOpen-market sale27,051$1.44$39KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 69 reporting institutions held 42.7M shares ($75.8M, 14.1% of shares outstanding).

#InstitutionSharesValue
1SUVRETTA CAPITAL MANAGEMENT, LLC12,341,266$22.1M
2MORGAN STANLEY8,955,967$16.0M
3MILLENNIUM MANAGEMENT LLC2,271,577$4.1M
4Bleichroeder LP2,000,000$3.6M
5Artia Global Partners LP1,806,939$3.2M
6Hennion & Walsh Asset Management, Inc.1,611,693$2.9M
7BlackRock, Inc.1,387,116$2.5M
8RENAISSANCE TECHNOLOGIES LLC1,250,794$2.2M
9GEODE CAPITAL MANAGEMENT, LLC1,230,409$2.2M
10VANGUARD CAPITAL MANAGEMENT LLC1,146,937$2.1M
11MARSHALL WACE, LLP1,011,744$1.8M
12BANK OF AMERICA CORP /DE/753,412$1.3M
13CHARLES SCHWAB INVESTMENT MANAGEMENT INC627,771$1.1M
14STATE STREET CORP556,845$997K
15VANGUARD FIDUCIARY TRUST CO538,371$964K